FRI0347 PREVALENCE OF OBESITY AND ITS LINK TO PSORIATIC ARTHRITIS (PSA) ACTIVITY AND RESPONSE TO THERAPY: DATA FROM THE RUSSIAN PSA REGISTRY (RU-PSART)
Authors: Y. Korsakova, E. Loginova, E. Gubar, E. Vasilenko, A. Vasilenko, N. Kuznetsova, I. Patrikeeva, T. Korotaeva, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2020)

Background: Obesity is a common comorbidity of psoriasis and PsA. It is connected to low-grade inflammation and it has a negative impact on the response to therapies. Although a high prevalence of obesity has been shown in a whole number of epidemiology and observational studies, its relationship to PsA activity has been less investigated. In the RU-PsART registry data was collected from 43 rheumatology centers of the Russian Federation Objectives: to evaluate the prevalence of obesity and its association to PsA activity as well as its impact on therapy response in real clinical practice Methods: 614 (M/F=331(54%)/283(46%) PsA pts fulfilling the CASPAR criteria were included from the RU-PsART cohort. Mean age 45.2±0.52 yrs, PsA duration 5.7±0.27 yrs, PsO duration 15.71±0.56 yrs, DAPSA 28.79±0.75. At baseline (BL) and 6 mo/12 mo of observation PsA activity was evaluated by Tender Joint Count (TJC68), Swollen Joint Count (SJC66); PGA, physician global assessment by Visual Analog Scale (VAS); PtGA VAS; PtPain VAS; DAPSA and body mass index (BMI, kg/m 2 ) were calculated. Pts were treated with conventional/target synthetic disease-modifying antirheumatic drugs csDMARDs (55%)/tsDMARDs (5%), biological DMARDs (23%), NSAID (17%) according to physician’s decision. At BL/6/12 mo all pts were categorized according to DAPSA as high activity (DAPSA&gt;28) and Moderate (Mo≤28)/Low Activity (LA≤14)/Remission DAPSA (REM≤4). All pts were divided into three groups according to BMI (kg/m 2 ): normal&lt;25, overweight &gt;25-30, obese&gt;30. M±m,%, multivariate analysis of variance (MANOVA), ANOVA, OR 95% (CI) were performed. All p&lt;0.05, were considered to indicate statistical significance Results: The baseline BMI was 27.7±0.23 kg/m 2 with the following BMI categories: normal - 212 pts (34.6%), overweight - 214 pts (34.8%) and obese - 187 (30.45%). In all pts DAPSA significantly improved to 16.11±0.82/14.71±1.17 at 6/12 mo accordingly. At BL and 6/12 mo of therapy DAPSA was significantly higher in the obese pts compared to the normal and the overweight pts despite of improvements seen in all groups (table 1). By the last visit significant differences were found in DAPSA depending on BMI at BL (ANOVA, p&lt;0.031). BMI&gt;30 at BL was associated with lower probability of DAPSA improvement from high activity to Mo/LA/REM state compared to normal BMI pts and the overweight pts: OR 2.484 (95% CI 1.135-5.439) and OR 2.346 (95% CI 1.07-5.143) accordingly (Fig 1) Table 1. Dynamics of DAPSA from BL to 6/12 mo depending on BMI categories. BMI (kg/m 2 ) DAPSA BL DAPSA 6 mo DAPSA 12 mo &lt;25 27.20 ± 1.15 13.84 ± 1.01 13.33 ± 1.53 25-30 26.93 ± 1.17 14.48 ± 1.43 13.83 ± 2.36 &gt;30 32.86 ± 1.57 21.19 ± 1.84 18.92 ± 2.54 Fig. 1. OR analysis of relationship between BMI at BL and treatment response. Conclusion: The high prevalence of overweight/obesity PsA pts was associated with higher PsA activity and lower response to therapy in our cohort Disclosure of Interests: Yulia Korsakova: None declared, Elena Loginova Speakers bureau: Janssen, ELENA GUBAR: None declared, Elizaveta Vasilenko: None declared, Aleksey Vasilenko: None declared, Natalia Kuznetsova: None declared, Irina Patrikeeva: None declared, Tatiana Korotaeva Grant/research support from: Pfizer, Consultant of: Abbvie, BIOCAD, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp &amp; Dohme, Novartis, Novartis-Sandoz, Pfizer, UCB, Speakers bureau: Abbvie, BIOCAD, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp &amp; Dohme, Novartis, Novartis-Sandoz, Pfizer, UCB, Evgeny Nasonov: None declared